NCT04971980View on ClinicalTrials.gov

Safety and Efficacy Study of Human Umbilical Cord-Derived Mesenchymal Stem Cells(BC-U001) for Rheumatoid Arthritis

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 12, 2021

Primary Completion Date

July 10, 2023

Study Completion Date

November 30, 2025

Conditions
Rheumatoid Arthritis
Interventions
DRUG

hUC-MSC infusion (BC-U001)

The participants are intravenously administered a single infusion of hUC-MSC at 0.5x10\^6 cells/kg body weight, 1.0x10\^6 cells/kg body weight, 1.5x10\^6 cells/kg body weight for low-dose cohort, medium-dose cohort and high-dose cohort respectively.

Trial Locations (1)

100730

Peking Union Medical College Hospital (Dongdan campus), Beijing

All Listed Sponsors
lead

Beijing Baylx Biotech Co., Ltd.

INDUSTRY